Skip to main content

Advertisement

Log in

Clinical trial of allogeneic cultured dermal substitutes for intractable skin ulcers

  • Original Article
  • Published:
Journal of Artificial Organs Aims and scope Submit manuscript

Abstract

The effect of allogeneic cultured dermal substitute (CDS) on wound healing was evaluated in 9 intractable skin ulcers in 5 patients who had failed to improve despite conventional topical treatment with basic fibroblast growth factor (bFGF) for more than 2 months. In general, the topical application of bFGF is effective in facilitating wound healing. However, skin regeneration was very slow in the present 9 cases. In this study, to improve the condition of these wounds, allogeneic CDS was applied once a week for 2 months. The wound healing process was evaluated, focusing on the reduction ratio of wound size through the granulation tissue formation associated with epithelialization. In all 9 cases, the wound size was successfully decreased after the application of CDS, and ulcers were completely resurfaced in 2 cases. In all cases, except the 2 cases showing complete wound closure, the mean wound size decreased to 33.3% of the original size, i.e., a mean reduction ratio of 33.3%. The present results indicate that allogeneic CDS can promote wound healing of intractable skin ulcers that fail to improve despite treatment with bFGF.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Kubo K, Kuroyanagi Y. Development of cultured dermal substitute composed of spongy matrix of hyaluronic acid and atelo-collagen combined with fibroblasts: fundamental evaluation. J Biomater Sci Polym Ed. 2003;14:625–41.

    Article  PubMed  CAS  Google Scholar 

  2. Kubo K, Kuroyanagi Y. Spongy matrix of hyaluronic acid and collagen as a cultured dermal substitute: evaluation in an animal test. J Artif Organs. 2003;6:64–70.

    Article  PubMed  CAS  Google Scholar 

  3. Kubo K, Kuroyanagi Y. Characterization of cultured dermal substitute composed of spongy matrix of hyaluronic acid and collagen combined with fibroblasts. J Artif Organs. 2003;6:138–44.

    PubMed  CAS  Google Scholar 

  4. Kubo K, Kuroyanagi Y. Effects of vascular endothelial growth factor released from cultured dermal substitute on proliferation of vascular endothelial cells in vitro. J Artif Organs. 2003;6:267–72.

    Article  PubMed  CAS  Google Scholar 

  5. Kuroyanagi Y, Kubo K, Matsui H, Kim HJ, Numari S, Mabuchi Y, Kagawa S. Establishment of banking system for allogeneic cultured dermal substitute. Artif Organs. 2004;28:13–21.

    Article  PubMed  Google Scholar 

  6. Kubo K, Kuroyanagi Y. Development of a cultured dermal substitute composed of a spongy matrix of hyaluronic acid and atelo-collagen combined with fibroblasts: cryopreservation. Artif Organs. 2004;28:182–8.

    Article  PubMed  Google Scholar 

  7. Kubo K, Kuroyanagi Y. The possibility of long-term cryopreservation of cultured dermal substitute. Artif Organs. 2005;29:800–5.

    Article  PubMed  CAS  Google Scholar 

  8. Kubo K, Kuroyanagi Y. A study of cytokines released form fibroblasts in culture dermal substitute. Artif Organs. 2005;29:845–9.

    Article  PubMed  CAS  Google Scholar 

  9. Hashimoto A, Kuroyanagi Y. Standardization for mass production of allogeneic cultured dermal substitute by measuring the amount of VEGF, bFGF, HGF, TGF-β, and IL-8. J Artif Organs. 2008;11:225–31.

    Article  PubMed  CAS  Google Scholar 

  10. Kashiwa N, Ito O, Ueda T, Kubo K, Matsui H, Kuroyanagi Y. Treatment of full-thickness skin defect with concomitant grafting of 6-fold extended mesh auto-skin and allogeneic cultured dermal substitute. Artif Organs. 2004;28:444–50.

    Article  PubMed  Google Scholar 

  11. Ohtani T, Okamoto K, Kaminaka C, Kishi T, Sakurane M, Yamamoto Y, Ueda K, Kubo K, Kuroyanagi Y, Furukawa F. Digital gangrene associated with idiopathic hypereosinophilia: treatment with allogeneic cultured dermal substitute. Eur J Dermatol. 2004;14:168–71.

    PubMed  Google Scholar 

  12. Moroi Y, Fujita S, Fukagawa S, Mashino T, Goto T, Masuda T, Urabe K, Kubo K, Matsui H, Kagawa S, Kuroyanagi Y, Furue M. Clinical evaluation of allogeneic cultured dermal substitutes for intractable skin ulcers after tumor resection. Eur J Dermatol. 2004;14:172–6.

    PubMed  Google Scholar 

  13. Hasegawa T, Suga Y, Mizoguchi M, Ikeda S, Ogawa H, Kubo K, Matsui H, Kagawa S, Kuroyanagi Y. Clinical trial of allogeneic cultured dermal substitute for the treatment of intractable skin ulcers in 3 patients with recessive dystrophic epidermolysis bullosa. J Am Acad Dermatol. 2004;50:803–4.

    Article  PubMed  Google Scholar 

  14. Hasegawa T, Suga Y, Mizoguchi M, Muramatsu S, Mizuno Y, Ogawa H, Kubo K, Kuroyanagi Y. An allogeneic cultured dermal substitute suitable for treating intractable skin ulcers and large skin defects prior to autologous skin grafting: three case reports. J Dermatol. 2005;32:715–20.

    PubMed  Google Scholar 

  15. Hasegawa T, Suga Y, Mizoguchi M, Muramatsu S, Mizuno Y, Haruna K, Ikeda S, Kuroyanagi Y, Ogawa H. Intractable venous leg ulcer treated successfully with allogeneic cultured dermal substitute. Scand J Plast Reconstr Surg Hand Surg. 2007;41:326–8.

    Article  PubMed  Google Scholar 

  16. Yonezawa M, Tanizaki H, Inoguchi N, Ishida M, Katoh M, Tachibana T, Miyachi Y, Kubo K, Kuroyanagi Y. Clinical study with allogeneic cultured dermal substitutes for chronic leg ulcers. Int J Dermatol. 2007;46:36–42.

    Article  PubMed  Google Scholar 

  17. Nishimoto J, Amoh Y, Tanabe K, Niiyama N, Katsuoka K, Kuroyanagi Y. Intractable leg ulcers associated with antiphospholipid syndrome with stasis dermatitis: treatment with allogeneic cultured dermal substitute. Eur J Dermatol. 2007;17(4):350–1.

    PubMed  Google Scholar 

  18. Yamada N, Uchinuma E, Kuroyanagi Y. Clinical trial of allogeneic cultured dermal substitutes for intractable skin ulcers of lower leg. J Artif Organs. 2008;11:100–3.

    Article  PubMed  CAS  Google Scholar 

  19. Yamada N, Uchinuma E, Matsumoto Y, Kuroyanagi Y. Comparative evaluation of re-epithelialization promoted by fresh or cryopreserved cultured dermal substitute. J Artif Organs. 2008;11:221–4.

    Article  PubMed  Google Scholar 

  20. Ohara N, Mihara S, Nihara H, Akimoto N, Madokoro N, Kawai M, Noda H, Hide M, Matsumoto Y, Kuroyanagi Y. A case of lower-extremity deep burn wounds with periosteal necrosis successfully treated by use of allogeneic cultured dermal substitute. J Artif Organs. 2010;13:101–5.

    Article  PubMed  Google Scholar 

  21. Clark RA. Continuing medical education. Cutaneous tissue repair: basic biologic considerations I. J Am Acad Dermatol. 1985;13:701–25.

    Article  PubMed  CAS  Google Scholar 

  22. Fu X, Shen Z, Chen Y. Basic fibroblast growth factor (bFGF) and wound healing: a multi-centers controlled clinical trial in 1024 cases. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 1998;12:209–11.

    PubMed  CAS  Google Scholar 

  23. Yamanaka K, Inaba T, Nomura E, Hurwitz D, Jones DA, Hakamada A, Isoda K, Kupper TS, Mizutani H. Basic fibroblasts growth factor treatment for skin ulceration in scleroderma. Cutis. 2005;76:373–6.

    PubMed  Google Scholar 

  24. Powell RJ, Simons M, Mendelsohn FO, Daniel G, Henry TD, Koga M, Morishita R, Annex BH. Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia. Circulation. 2008;118:58–65.

    Article  PubMed  CAS  Google Scholar 

  25. Anitua E, Aguirre JJ, Algorta J, Ayerdi E, Cabezas AI, Orive G, Andia I. Effectiveness of autologous preparation rich in growth factors for the treatment of chronic cutaneous ulcers. J Biomed Mater Res B Appl Biomater. 2008;84:415–21.

    PubMed  Google Scholar 

  26. Uchi H, Igarashi A, Urabe K, Koga T, Nakayama J, Kawamori R, Tamaki K, Hirakata H, Ohura T, Furue M. Clinical efficacy of basic growth factor (bFGF) for diabetic ulcer. Eur J Dermatol. 2009;19:461–8.

    PubMed  Google Scholar 

  27. Przybylski M. A review of the current research on the role of bFGF and VEGF in angiogenesis. J Wound Care. 2009;18:516–9.

    PubMed  CAS  Google Scholar 

  28. Yan X, Chen B, Lin Y, Li Y, Xiao Z, Hou X, Tan Q, Dai J. Acceleration of diabetic wound healing by collagen-binding vascular endothelial growth factor in diabetic rat model. Diabetes Res Clin Pract. 2010;90:66–72.

    Article  PubMed  CAS  Google Scholar 

  29. Culp LA, Murray BA, Rollins BJ. Fibronectin and proteoglycans as determinants of cell-substratum adhesion. J Supramol Struct. 1979;11:401–27.

    Article  PubMed  CAS  Google Scholar 

  30. Benedetti L, Cortivo R, Berti T, Berti A, Pea F, Mazzo M, Moras M, Abatangelo G. Biocompatibility and biodegradation of different hyaluronan derivatives (Hyaff) implanted in rats. Biomaterials. 1993;14:1154–60.

    Article  PubMed  CAS  Google Scholar 

  31. Postlethwaite AE, Seyer JM, Kang AH. Chemotactic attraction of human fibroblasts to type I, II, and III collagens and collagen-derived peptides. Proc Natl Acad Sci USA. 1978;75:871–5.

    Article  PubMed  CAS  Google Scholar 

  32. Mooney DJ, Mikos AG. The promise of tissue engineering: growing new organs. Sci Am. 1999;280:38–43.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Naoto Yamada.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yamada, N., Uchinuma, E. & Kuroyanagi, Y. Clinical trial of allogeneic cultured dermal substitutes for intractable skin ulcers. J Artif Organs 15, 193–199 (2012). https://doi.org/10.1007/s10047-011-0618-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10047-011-0618-0

Keywords

Navigation